Most cited papers from Carmot Therapeutics (United States)
What are the most cited papers from Carmot Therapeutics (United States)?
The most cited paper from Carmot Therapeutics (United States) is "Twenty years on: the impact of fragments on drug discovery" (Daniel A. Erlanson, Stephen W. Fesik, Roderick E. Hubbard et al., 2016), with 1,016 citations. Next come "Introduction to Fragment-Based Drug Discovery" (264) and "Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia" (238).
Showing 26 of 26 papers. Every paper is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Twenty years on: the impact of fragments on drug discovery Daniel A. Erlanson, Stephen W. Fesik, Roderick E. Hubbard et al. · Nature Reviews Drug Discovery | 15 Jul 2016 | 1,016 |
| 2 | Introduction to Fragment-Based Drug Discovery Daniel A. Erlanson · Topics in current chemistry | 2011 | 264 |
| 3 | Design Principles for Fragment Libraries: Maximizing the Value of Learnings from Pharma Fragment-Based Drug Discovery (FBDD) Programs for Use in Academia György Miklós Keserű, Daniel A. Erlanson, György G. Ferenczy et al. · Journal of Medicinal Chemistry | 28 Apr 2016 | 238 |
| 4 | Learning from our mistakes: The ‘unknown knowns’ in fragment screening Ben J. Davis, Daniel A. Erlanson · Bioorganic & Medicinal Chemistry Letters | 18 Mar 2013 | 146 |
| 5 | Validity of Ligand Efficiency Metrics Christopher W. Murray, Daniel A. Erlanson, Andrew L. Hopkins et al. · ACS Medicinal Chemistry Letters | 9 May 2014 | 138 |
| 6 | Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures Daniel A. Erlanson, Ben J. Davis, Wolfgang Jahnke · Cell chemical biology | 25 Oct 2018 | 129 |
| 7 | Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C Youngsook Shin et al. · ACS Medicinal Chemistry Letters | 20 Aug 2019 | 110 |
| 8 | Fragment-to-Lead Medicinal Chemistry Publications in 2015 Christopher N. Johnson, Daniel A. Erlanson, Christopher W. Murray et al. · Journal of Medicinal Chemistry | 14 Oct 2016 | 65 |
| 9 | Fragment-to-Lead Medicinal Chemistry Publications in 2017 Paul N. Mortenson, Daniel A. Erlanson, Iwan J. P. de Esch et al. · Journal of Medicinal Chemistry | 21 Nov 2018 | 64 |
| 10 | Fragment-to-Lead Medicinal Chemistry Publications in 2016 Christopher N. Johnson, Daniel A. Erlanson, Wolfgang Jahnke et al. · Journal of Medicinal Chemistry | 31 Oct 2017 | 61 |
| 11 | A maternal brain hormone that builds bone Muriel E. Babey, William C. Krause, Kun Chen et al. · Nature | 10 Jul 2024 | 50 |
| 12 | The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results Gail D. Lewis Phillips et al. · Nature Communications | 11 Jan 2024 | 50 |
| 13 | Learning from PAINful lessons Daniel A. Erlanson · Journal of Medicinal Chemistry | 24 Feb 2015 | 33 |
| 14 | A Universal Isocyanide for Diverse Heterocycle Syntheses Pravin Sahebrao Patil, Kareem Khoury, Eberhardt Herdtweck et al. · Organic Letters | 29 Oct 2014 | 25 |
| 15 | Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy Rubén Rodríguez, Anne C. Hergarden, Shyam Krishnan et al. · Cell Reports Medicine | Jun 2025 | 18 |
| 16 | Co(II) and Ni(II) binding of the Escherichia coli transcriptional repressor RcnR orders its N terminus, alters helix dynamics, and reduces DNA affinity Hsin-Ting Huang, Cedric E. Bobst, Jeffrey S. Iwig et al. · Journal of Biological Chemistry | 17 Nov 2017 | 13 |
| 17 | Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity Manu V. Chakravarthy et al. · Molecular Metabolism | 28 Nov 2025 | 6 |
| 18 | A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II Snezana Milanovic, Robert Lew, Kuangnan Xiong et al. · Diabetes Obesity and Metabolism | 22 Oct 2025 | 4 |
| 19 | The Goldilocks for chronic weight management—Balancing quantity with quality of weight loss Kim Henriksen, Manu V. Chakravarthy, Cecilie Liv Bager et al. · Diabetes Obesity and Metabolism | 10 Apr 2025 | 4 |
| 20 | An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I Snezana Milanovic, Robert Lew, Kuangnan Xiong et al. · Diabetes Obesity and Metabolism | 22 Oct 2025 | 3 |
| 21 | Development of DHES0815A; a novel HER2-directed antibody-drug conjugate comprised of a reduced potency mono-alkylating agent linked to a domain I binding HER2 antibody Gail Lewis et al. · Research Square | 21 Dec 2022 | 3 |
| 22 | Fragment-based lead discovery Daniel A. Erlanson · The biomedical & life sciences collection. | 23 Sep 2013 | 2 |
| 23 | Foreword: Pacific Fragments Daniel Erlanson · Molecules | 16 Jul 2016 | 1 |
| 24 | Improved Sway Velocities and Directional Balance Improvement in Two Individuals with Spinal Cerebellar Ataxia with Balance-Based Torso-Weighting: A Case Series Report (P2.130) Cynthia Gibson‐Horn, Susan Perlman · Neurology | 6 Apr 2015 | 1 |
| 25 | A Vision for the Future of Molecular Cancer Therapeutics Daniel K. Nomura · Molecular Cancer Therapeutics | 2 May 2025 | 0 |
| 26 | PDK1 inhibitor SNS-510 shows synergy with targeted cancer therapies in solid tumor and hematologic cancer models Pietro Taverna, Steven G. Hansen, Judith Ann Fox · European Journal of Cancer | Oct 2020 | 0 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.